GFAP and Alzheimer disease: Furthermore, we surmise that the reliability of these blood-based markers such as GFAP should be temporarily paused until we carefully appraise the extent of wreckage in the glymphatic excretory pathways and their ensuing impact in undermining the active hauling of these astroglial markers safely into the systemic circulation in TBI and AD.